Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3591-3597

  O'Brien, Matthew Frank ^a   Cronin, Angel M ^a   Fearn, Paul A ^a   Smith, Brandon ^a   Stasi, Jason ^a   Guillonneau, Bertrand ^a   Scardino, Peter T ^a   Eastham, James A ^a   Vickers, Andrew J ^a   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; VELOCITY; ANALYSIS OF VARIANCE; BLOOD; CANCER INVASION; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TIME; TUMOR RECURRENCE;

ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 68949121119     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9794     Document Type: Article

References (31)

1. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
2. D'Amico AV, Renshaw AA, Sussman B, et al: Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294:440-447, 2005
3. Daskivich TJ, Regan MM, Oh WK: Prostate specific antigen doubling time calculation: Not as easy as 1, 2, 4. J Urol 176:1927-1937, 2006
4. Svatek RS, Shulman M, Choudhary PK, et al: Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106:1047-1053, 2006
5. Yu X, Han M, Loeb S, et al: Comparison of methods for calculating prostate specific antigen velocity. J Urol 176:2427-2431, 2006
6. Stephenson AJ, Scardino PT, Eastham JA, et al: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715-717, 2006
7. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997
8. Soloway MS, Pareek K, Sharifi R, et al: Neo-adjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002
9. Stephenson AJ, Kattan MW, Eastham JA, et al: Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 24:3973-3978, 2006
10. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
11. Egawa S, Arai Y, Tobisu K, et al: Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3:269-274, 2000
12. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
13. Hanks GE, Hanlon AL, Lee WR, et al: Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34:549-553, 1996
14. Lee AK, Levy LB, Cheung R, et al: Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456-462, 2005
15. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
16. Sengupta S, Myers RP, Slezak JM, et al: Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174:2191-2196, 2005
17. Shulman MJ, Karam JA, Benaim EA: Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 63: 732-736, 2004
18. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005
19. Stephenson AJ, Aprikian AG, Souhami L, et al: Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59:652-656, 2002
20. Ward JF, Zincke H, Bergstralh EJ, et al: Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172: 2244-2248, 2004
21. Trapasso JG, deKernion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994
22. Rozhansky F, Chen MH, Cox MC, et al: Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106:63-67, 2006
23. Thiel R, Pearson JD, Epstein JI, et al: Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology 49:716-720, 1997
24. Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529-534, 2006
25. Memorial Sloan-Kettering Cancer Center: Calculator MPDT: Mskcc.org prediction tools - PSA doubling time. http://www.mskcc.org/
26. Memorial Sloan-Kettering Cancer Center: Calculator MPV: Mskcc.org prediction tools - PSA doubling time. http://www.mskcc.org/
27. Patel DA, Presti JC Jr, McNeal JE, et al: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23:6157-6162, 2005
28. Vickers A, Savage C, O'Brien M, et al: A systematic review of pretreatment PSA velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398-403, 2009
29. Etzioni RD, Ankerst DP, Weiss NS, et al: Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 99:1510-1515, 2007
30. Carter HB, Ferrucci L, Kettermann A, et al: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527, 2006
31. Schroder FH, Roobol MJ, van der Kwast TH, et al: Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49:460-465, 2006